This story is part of STAT’s quarterly series Something Ventured, which looks at early-stage startups. You can read the earlier stories in the series here.
Early-stage biotech companies are almost always raising money. That cash, CEOs say, fuels their amazing science and potentially amazing drugs.
About the Author Reprints
